Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome.

Jolley J.

Clin Exp Gastroenterol. 2011;4:43-8. doi: 10.2147/CEG.S18051. Epub 2011 Apr 18.

PMID:
21694871
[PubMed]
Free PMC Article
2.

Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.

Meyrat P, Safroneeva E, Schoepfer AM.

Aliment Pharmacol Ther. 2012 Dec;36(11-12):1084-93. doi: 10.1111/apt.12087. Epub 2012 Oct 16.

PMID:
23066911
[PubMed - indexed for MEDLINE]
3.

Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.

Weinstock LB, Geng B, Brandes SB.

Can J Urol. 2011 Aug;18(4):5826-30.

PMID:
21854715
[PubMed - indexed for MEDLINE]
4.

Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy.

Weinstock LB, Fern SE, Duntley SP.

Dig Dis Sci. 2008 May;53(5):1252-6. Epub 2007 Oct 13.

PMID:
17934858
[PubMed - indexed for MEDLINE]
5.

Rifaximin in irritable bowel syndrome: rationale, evidence and clinical use.

Saadi M, McCallum RW.

Ther Adv Chronic Dis. 2013 Mar;4(2):71-5. doi: 10.1177/2040622312472008.

PMID:
23556126
[PubMed]
Free PMC Article
6.

Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome.

Boltin D, Perets TT, Shporn E, Aizic S, Levy S, Niv Y, Dickman R.

Ann Clin Microbiol Antimicrob. 2014 Oct 17;13:49. doi: 10.1186/s12941-014-0049-x.

PMID:
25319626
[PubMed - in process]
Free PMC Article
7.

[Variation of intestinal fermentative profile after sequential therapy with rifaximin/probiotics].

Dima G, Peralta D, Novillo A, Lasa J, Besasso H, Soifer L.

Acta Gastroenterol Latinoam. 2012 Jun;42(2):99-104. Spanish.

PMID:
22876711
[PubMed - indexed for MEDLINE]
8.

Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.

Moraru IG, Portincasa P, Moraru AG, Diculescu M, Dumitraşcu DL.

Rom J Intern Med. 2013 Jul-Dec;51(3-4):143-7.

PMID:
24620626
[PubMed - indexed for MEDLINE]
9.

Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin.

Cuoco L, Salvagnini M.

Minerva Gastroenterol Dietol. 2006 Mar;52(1):89-95.

PMID:
16554709
[PubMed - indexed for MEDLINE]
10.
11.

Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.

Peralta S, Cottone C, Doveri T, Almasio PL, Craxi A.

World J Gastroenterol. 2009 Jun 7;15(21):2628-31.

PMID:
19496193
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.

Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundarò C, Gasbarrini A.

Eur Rev Med Pharmacol Sci. 2013 May;17(10):1314-20.

PMID:
23740443
[PubMed - indexed for MEDLINE]
Free Article
13.

Rifaximin treatment for symptoms of irritable bowel syndrome.

Fumi AL, Trexler K.

Ann Pharmacother. 2008 Mar;42(3):408-12. doi: 10.1345/aph.1K345. Epub 2008 Feb 26. Review.

PMID:
18303148
[PubMed - indexed for MEDLINE]
14.

Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, Mareya SM, Shaw AL, Bortey E, Forbes WP; TARGET Study Group.

N Engl J Med. 2011 Jan 6;364(1):22-32. doi: 10.1056/NEJMoa1004409.

PMID:
21208106
[PubMed - indexed for MEDLINE]
Free Article
15.

A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.

Zhao J, Zheng X, Chu H, Zhao J, Cong Y, Fried M, Fox M, Dai N.

Neurogastroenterol Motil. 2014 Jun;26(6):794-802. doi: 10.1111/nmo.12331. Epub 2014 Mar 18.

PMID:
24641100
[PubMed - in process]
16.

Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics.

Esposito I, de Leone A, Di Gregorio G, Giaquinto S, de Magistris L, Ferrieri A, Riegler G.

World J Gastroenterol. 2007 Dec 7;13(45):6016-21.

PMID:
18023092
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial.

Pimentel M, Park S, Mirocha J, Kane SV, Kong Y.

Ann Intern Med. 2006 Oct 17;145(8):557-63.

PMID:
17043337
[PubMed - indexed for MEDLINE]
18.

Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution.

Parodi A, Dulbecco P, Savarino E, Giannini EG, Bodini G, Corbo M, Isola L, De Conca S, Marabotto E, Savarino V.

J Clin Gastroenterol. 2009 Nov-Dec;43(10):962-6. doi: 10.1097/MCG.0b013e3181a099a5.

PMID:
19525858
[PubMed - indexed for MEDLINE]
19.

Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls.

Walters B, Vanner SJ.

Am J Gastroenterol. 2005 Jul;100(7):1566-70.

PMID:
15984983
[PubMed - indexed for MEDLINE]
20.

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.

Menees SB, Maneerattannaporn M, Kim HM, Chey WD.

Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36. doi: 10.1038/ajg.2011.355. Epub 2011 Nov 1. Review.

PMID:
22045120
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk